Leading International Cannabis Expert Joins Valens Board of Directors
Kelowna, B.C., May 13th 2019 – Valens GroWorks Corp. (CSE: VGW) (OTC: VGWCF) (the “Company” or “Valens”), a multi-licensed, vertically integrated provider of cannabis products and services focused on various proprietary extraction methodologies, distillation, cannabinoid isolation and purification, as well as associated quality testing announced today that Deepak Anand has been appointed to its Board of Directors as an independent member.
Mr. Anand is recognized as a thought leader in the global cannabis space. He currently serves as the co-founder & CEO of Materia Ventures, a European-focused supply and distribution company for medical cannabis and CBD products. He previously served as vice president of business development and government relations at a Canadian cannabis consulting firm; vice president of a Health Canada-licensed producer; and as a board member for various pharmaceutical associations across Canada, the United States and Europe.
“Over the last decade I have had the honour of working with many licensed producers, doctors, patients, policymakers and senior government officials in the cannabis industry,” says Deepak Anand. “I look forward to leveraging the knowledge and expertise I gained in the industry to guide Valens as they enter an exciting new chapter of rapid domestic and international growth.”
“We are extremely excited to announce the joining of Mr. Anand to our board,” says Tyler Robson, CEO of Valens GroWorks. “No stranger to the international cannabis sector, his regulatory expertise and global cannabis network is unparalleled. Bringing this international industry-specific knowledge to our board will be extremely valuable as we continue to execute on our growth strategies.”
About Valens GroWorks
Valens GroWorks Corp. is a research-driven, vertically integrated Canadian cannabis company focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification, as well as associated quality testing with three wholly-owned subsidiaries located in and around Kelowna, BC. Subsidiary Valens Agritech (“VAL”) holds a license to cultivate cannabis and produce cannabis oil under the Cannabis Act, as well as a license to conduct analytical testing for the cannabis industry. VAL currently has extraction processing and supply agreements with various leading producers across Canada. Subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. Subsidiary Valens Farms is in the process of becoming a purpose-built facility in compliance with European Union (EU) Good Manufacturing Practices (GMP) standards, ensuring the product from this facility can be exported anywhere in the world where Cannabis is nationally legal for medical or adult usage purposes. For more information, please visit Valens GroWorks or view the company’s Investor’s Deck.
For further information, please contact:
Valens GroWorks Corp.
U.S. / Europe Investors
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
212.896.1233 / 212.896.1203
KCSA Strategic Communications
Notice Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.